The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death.

[1]  M. Jordan,et al.  Microtubule dynamics: taking aim at a moving target. , 1995, Chemistry & biology.

[2]  C. Kanthou,et al.  The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. , 2002, Blood.

[3]  C. Chi,et al.  Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. , 1998, Anticancer research.

[4]  B Vojnovic,et al.  Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. , 1999, Cancer research.

[5]  C. Kanthou,et al.  The biology of the combretastatins as tumour vascular targeting agents , 2002, International journal of experimental pathology.

[6]  R. Berti,et al.  Locomotory response ofPhreatichthys andruzzii Vinciguerra (Pisces, Cyprinidae) to chemical signals of conspecifics and of closely related species , 1989, Experientia.

[7]  D. Chaplin,et al.  Tumour vasculature as a target for cancer therapy. , 1999, British journal of cancer.

[8]  H. Joshi,et al.  Sustained Activation of p34 cdc2 Is Required for Noscapine-induced Apoptosis* , 2001, The Journal of Biological Chemistry.

[9]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[10]  D. Chaplin,et al.  Anti—vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid , 1995, International journal of cancer.

[11]  E. Lazarides,et al.  Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway , 1995, Molecular medicine.

[12]  R. Hesketh,et al.  Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. , 2002, The American journal of pathology.

[13]  P. Nurse.  Universal control mechanism regulating onset of M-phase , 1990, Nature.

[14]  L. Meijer,et al.  cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF , 1988, Cell.

[15]  S. Jee,et al.  Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[16]  J. Denekamp,et al.  Vinca alkaloids: anti-vascular effects in a murine tumour. , 1993, European journal of cancer.

[17]  F. Lee,et al.  Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. , 2001, Anticancer research.

[18]  D. Ribatti,et al.  Docetaxel versus paclitaxel for antiangiogenesis. , 2002, Journal of hematotherapy & stem cell research.

[19]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[20]  D. Alberts,et al.  Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 , 1989, Experientia.

[21]  D. Ribatti,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 2016 .

[22]  Z. Darżynkiewicz,et al.  Flow cytometry in analysis of cell cycle and apoptosis. , 2001, Seminars in hematology.

[23]  J. Mester,et al.  Cellular effects of purvalanol A: A specific inhibitor of cyclin‐dependent kinase activities , 2002, International journal of cancer.

[24]  L. Meijer,et al.  p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol , 2002, Oncogene.

[25]  P. Chadebech,et al.  Up‐regulation of cdc2 protein during paclitaxel‐induced apoptosis , 2000, International journal of cancer.

[26]  A. Boulares,et al.  Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. , 1998, Cancer research.

[27]  M. Jordan,et al.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin. , 2002, Current medicinal chemistry. Anti-cancer agents.

[28]  R. Mohammad,et al.  Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  R. Kerbel,et al.  Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. , 2002, Cancer research.

[30]  Stephen J. Elledge,et al.  Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.

[31]  M. Andreeff,et al.  Accumulation of cyclin B1, activation of cyclin B1‐dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol , 1998, International journal of cancer.

[32]  R M Chau,et al.  [Cell cycle and apoptosis]. , 1996, Sheng li ke xue jin zhan [Progress in physiology].

[33]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[34]  B Vojnovic,et al.  Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. , 2001, Cancer research.

[35]  M. Stratford,et al.  The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. , 2002, International journal of oncology.

[36]  Denekamp.  The tumour microcirculation as a target in cancer therapy: a clearer perspective , 1999, European journal of clinical investigation.

[37]  M. Willingham,et al.  Apoptotic cell death induced by baccatin III, a precursor of paclitaxel, may occur without G(2)/M arrest. , 1999, Cancer chemotherapy and pharmacology.

[38]  Martin A Lodge,et al.  Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Lambin,et al.  Vascular targeting effect of combretastatin A‐4 phosphate dominates the inherent angiogenesis inhibitory activity , 2003, International journal of cancer.

[40]  J. Pouysségur,et al.  Confluence of Vascular Endothelial Cells Induces Cell Cycle Exit by Inhibiting p42/p44 Mitogen-Activated Protein Kinase Activity , 1999, Molecular and Cellular Biology.

[41]  J. Lacal,et al.  Rho signals to cell growth and apoptosis. , 2001, Cancer letters.

[42]  Korey R. Johnson,et al.  Nuclear Factor-κB/IκB Signaling Pathway May Contribute to the Mediation of Paclitaxel-induced Apoptosis in Solid Tumor Cells , 2000 .

[43]  G. Tozer,et al.  Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. , 1997, Cancer research.

[44]  L. Thomsen,et al.  Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. , 1991, European journal of cancer.

[45]  W. Fan,et al.  Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. , 2000, Cancer research.

[46]  M. Cragg,et al.  Mitotic death: a mechanism of survival? A review , 2001, Cancer Cell International.

[47]  Takashi Takahashi,et al.  Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. , 2003, The American journal of pathology.

[48]  G. Giaccone,et al.  Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.